Comparative effectiveness of bivalent BA.4–5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: A nationwide cohort study
In immunocompromised individuals, vaccination with bivalent BA.4-5 or BA.1 booster lowered the risk of Covid-19-related hospitalization and death over a follow-up period of 9 months. The effectiveness was highest during the first months since vaccination with subsequent gradual waning.
Authors
- Niklas Andersson (ORCID: https://orcid.org/0000-0001-9785-7462)
- Jori Perälä (ORCID: https://orcid.org/0009-0006-7216-791X)
- Anders Hviid (ORCID: https://orcid.org/0000-0002-7509-9127)
- Emilia Myrup Thiesson (ORCID: https://orcid.org/0000-0001-6258-4177)
- Nicklas Pihlström (ORCID: https://orcid.org/0000-0001-6812-0971)
- Mie Agermose Gram (ORCID: https://orcid.org/0000-0001-7908-0039)
- Eero Poukka (ORCID: https://orcid.org/0000-0001-5776-5897)
- Tuija Leino (ORCID: https://orcid.org/0000-0003-0501-8333)
- Rickard Ljung (ORCID: https://orcid.org/0000-0002-0654-4530)
Institutions
- Statens Serum Institut (DK)
- University of Copenhagen (DK)
- Medical Products Agency (SE)
- University of Helsinki (FI)
- Karolinska Institutet (SE)
- Finnish Institute for Health and Welfare (FI)
Publication Details
- Journal
- Journal of Infection
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1016/j.jinf.2024.106261
- Citations
- 3
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- Pfizer
- Sanofi
- Suomen Lääketieteen Säätiö
- Lundbeckfonden
- Novo Nordisk
- Novo Nordisk Fonden
- Danmarks Frie Forskningsfond
- European Medicines Agency
- H. Lundbeck A/S